EC Number |
Disease |
PubMed ID |
Title of Publication |
Category |
Confidence Level |
---|
1.1.98.3 | Infections |
26474057 |
In Vivo Activity of the Benzothiazinones PBTZ169 and BTZ043 against Nocardia brasiliensis. |
causal interaction therapeutic application unassigned |
3 4 0 |
1.1.98.3 | Infections |
32342688 |
Optimization of Hydantoins as Potent Antimycobacterial Decaprenylphosphoryl-?-d-Ribose Oxidase (DprE1) Inhibitors. |
ongoing research therapeutic application unassigned |
2 1 0 |
1.1.98.3 | Infections |
34370580 |
Comparative Analysis of Pharmacodynamics in the C3HeB/FeJ Mouse Tuberculosis Model for DprE1 inhibitors TBA-7371, PBTZ169 and OPC-167832. |
diagnostic usage ongoing research therapeutic application unassigned |
3 2 4 0 |
1.1.98.3 | Mycetoma |
26474057 |
In Vivo Activity of the Benzothiazinones PBTZ169 and BTZ043 against Nocardia brasiliensis. |
causal interaction therapeutic application unassigned |
3 4 0 |
1.1.98.3 | Tuberculosis |
20086151 |
Clinical isolates of Mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinones. |
diagnostic usage ongoing research unassigned |
1 1 0 |
1.1.98.3 | Tuberculosis |
20828197 |
Benzothiazinones: prodrugs that covalently modify the decaprenylphosphoryl-?-D-ribose 2'-epimerase DprE1 of Mycobacterium tuberculosis. |
unassigned |
0 |
1.1.98.3 | Tuberculosis |
21676874 |
Pseudomonas aeruginosa D-Arabinofuranose Biosynthetic Pathway and Its Role in Type IV Pilus Assembly. |
unassigned |
0 |
1.1.98.3 | Tuberculosis |
22733761 |
Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors. |
therapeutic application unassigned |
3 0 |
1.1.98.3 | Tuberculosis |
22926573 |
In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis. |
therapeutic application unassigned |
1 0 |
1.1.98.3 | Tuberculosis |
23184707 |
Crystal structure of decaprenylphosphoryl-?- D-ribose 2'-epimerase from Mycobacterium smegmatis. |
therapeutic application unassigned |
3 0 |